The Life Sciences team advised SonoThera on its oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines. The financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors ARCH Venture Partners, Alexandria Venture Investments, Duquesne Family Office, Illumina Ventures, Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation — JJDC, Inc., Medical Excellence Capital, RA Capital, and Vertex Ventures HC.
SonoThera is developing an ultrasound-mediated nonviral genetic medicine platform designed to deliver the next generation of safe, targeted, and redosable genetic medicines. By integrating proprietary RIPPLE™ ultrasound delivery with PORE™ payload engineering, the company is advancing a broad range of genetic medicine approaches, including DNA and RNA therapeutics, gene editing, and gene silencing. SonoThera's platform is designed to enable precise, durable gene expression across multiple tissues while addressing key limitations associated with viral delivery approaches. The company is advancing a pipeline of genetic medicines for serious diseases, including Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease.
The Goodwin team was led by Yasin Akbari, Evan Lee, Candace Hagey, and Kingsley Taft, and included Ari Kazanjian, Rich Matheny, Gozde Guckaya, Maggie Wong, and Kathy Georgian.